Opendata, web and dolomites

NGN-PET SIGNED

Modelling Neuron-Glia Networks into a drug discovery platform for Pain Efficacious Treatments - Sofia ref.: 116072

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NGN-PET project word cloud

Explore the words cloud of the NGN-PET project. It provides you a very rough idea of what is the project "NGN-PET" about.

models    tool    solutions    assays    neuronal    pathological    forming    chemotherapy    cells    altered    neuron    rat    therapies    schwann    activates    interplay    identification    discovery    basis    compound    disciplinary    knowhow    neurons    translation    hts    underlying    molecular    vitro    glial    injury    ipscs    team    throughput    co    quality    pet    treat    frequently    technologies    nerve    stem    interrogated    expertise    components    pose    neuropathic    pain    translate    subsequently    therapeutic    rodent    cultures    situation    circuitry    np    industrial    nociceptors    chronification    microglia    disease    cellular    central    demands    validation    patients    predictive    recapitulate    carefully    model    ngn    human    chronic    interactions    hence    screening    preclinical    poorly    cell    pharmaceutical    platforms    academic    life    interdisciplinary    builds    drug    mechanism    decipher    peripheral    tools    mechanisms    vivo    treatments    understand   

Project "NGN-PET" data sheet

The following table provides information about the project.

Coordinator
AXXAM SPA 

Organization address
address: VIA MEUCCI 3
city: BRESSO MILANO
postcode: 20091
website: www.axxam.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://ngn-pet.com/
 Total cost 3˙050˙000 €
 EC max contribution 1˙500˙000 € (49%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-07-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AXXAM SPA IT (BRESSO MILANO) coordinator 450˙000.00
2    KING'S COLLEGE LONDON UK (LONDON) participant 450˙000.00
3    LIFE AND BRAIN GMBH DE (BONN) participant 450˙000.00
4    NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN DE (REUTLINGEN) participant 150˙000.00
5    ESTEVE PHARMACEUTICALS, SA ES (BARCELONA) participant 0.00
6    GRUNENTHAL GMBH DE (AACHEN) participant 0.00

Map

 Project objective

Chronic Neuropathic Pain is frequently associated with peripheral nerve injury or disease. Peripheral injury activates both neuronal and glial components of the peripheral and central cellular circuitry. While it is widely known that the subsequently altered interactions between neurons and glial cells contribute to pain development and to its chronification, the underlying mechanisms are poorly understood. Developing mechanism-based therapies targeting neuron-glial interactions to treat chronic pain will be crucial for improving the quality of life of many patients. Hence the development of novel therapeutic solutions represents a major challenge that demands a multi-disciplinary approach to decipher and understand pathological mechanisms and to translate them into predictive tools for drug development. The NGN-PET consortium addresses this challenge by forming a highly interdisciplinary team that builds upon expertise in areas of academic research on pain mechanisms, industrial knowhow on human stem cell-based tool development, HTS technologies and drug discovery. To achieve its goal we will develop preclinical model systems and assays which recapitulate the human in vivo situation and which can be interrogated for the identification, validation of molecular targets and the development new treatments. A focus of the project will be chemotherapy induced NP and the interplay between nociceptors, microglia and Schwann cells. NGN-PET will carefully characterize rodent in vivo and in vitro models to identify these mechanisms, and will develop rat and human iPSCs based in vitro systems of neuron-glial co-cultures that can be interrogated for targets and used for compound identification and validation. NGN-PET will thus pose the basis for the translation of these model systems into high throughput screening platforms for pharmaceutical research and drug discovery.

 Deliverables

List of deliverables.
Interim dissemination and outreach report Documents, reports 2020-04-08 22:25:47
Data Management Plan Documents, reports 2020-04-08 22:25:47

Take a look to the deliverables list in detail:  detailed list of NGN-PET deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NGN-PET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NGN-PET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More  

NEURONET (2019)

Efficiently Networking European Neurodegeneration Research

Read More  

VITAL (2019)

Vaccines and Infectious Diseases in the Ageing PopuLation

Read More